Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Gerrit J. Schuurhuis, Michael Heuser, Sylvie Freeman, Marie Christine Béne, Francesco Buccisano, Jacqueline Cloos, David Grimwade, Torsten Haferlach, Robert K. Hills, Christopher S. Hourigan, Jeffrey L. Jorgensen, Wolfgang Kern, Francis Lacombe, Luca Maurillo, Claude Preudhomme, Bert A. van der Reijden, Christian Thiede, Adriano Venditti, Paresh Vyas, Brent L. WoodRoland B. Walter, Konstanze Döhner, Gail J. Roboz, Gert J. Ossenkoppele

Research output: Contribution to journalArticlepeer-review

361 Scopus citations


Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multiparameter flow cytometry and molecular protocols, but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRD in clinical practice. The work was accomplished over 2 years, during 4 meetings by a specially designated MRD Working Party of the European LeukemiaNet. The group included 24 faculty with expertise in AML hematopathology, molecular diagnostics, clinical trials, and clinical medicine, from 19 institutions in Europe and the United States.

Original languageEnglish (US)
Pages (from-to)1275-1291
Number of pages17
Issue number12
StatePublished - Mar 22 2018
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party'. Together they form a unique fingerprint.

Cite this